Impact of impurities on IC 50 values of P450 inhibitors

Drug Metabolism Letters

Volumn 5, Issue 3, 2011, Pages 156-162

  Huang, Zeqi ^a  

^a CEPHALON INC   (United States)

Author keywords

Cytochrome P450; IC 50; Impurity; Inhibition

Indexed keywords

CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; FLUOXETINE; FLUVOXAMINE; IBUPROFEN; QUINIDINE; ENZYME INHIBITOR;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG IMPURITY; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SIMULATION; DRUG ANTAGONISM; DRUG CONTAMINATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; LIVER MICROSOME; METABOLISM; METHODOLOGY;

CIMETIDINE; CYTOCHROME P-450 CYP2D6; DRUG CONTAMINATION; DRUG DISCOVERY; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER;

EID: 80052732806     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231211796905008     Document Type: Article

References (23)

1. Yan, B.; Fang, L.; Zhao, J.; Irving, M.M. Analytical techniques applied in the combinatorial synthesis large drug discovery libraries. Analytical Sciences, 2001, 17, i487-i490.
2. Gonzalez, P.; Polli, J.E. Impact of impurity on kinetic estimates from transport and inhibition studies. J. Pharmacol. Exp. Ther., 2008, 326, 296-305.
3. Sigvardson, K.W.; Adams, S.P.; Barnes, T.B.; Blom, K.F.; Fortunak, J.M.; Haas, M.J.; Reilly, K.L.; Repta, A.J.; Nemeth, G.A. The isolation and identification of a toxic impurity in XP315 drug substance. J. Pharm. Biomed. Anal., 2002, 27, 327-334.
4. International Conference on Harmonisation; revised guidance on Q3A impurities in new drug substances; availability. Notice. Fed. Regist., 2003, 68, 6924-6925.
5. Lehr, G.J.; Barry, T.L.; Franolic, J.D.; Petzinger, G.; Scheiner, P. LC determination of impurities in methoxsalen drug substance: isolation and identification of isopimpinellin as a major impurity by atmospheric pressure chemical ionization LC/MS and NMR. J. Pharm. Biomed. Anal., 2003, 33, 627-637.
6. Franolic, J.D.; Lehr, G.J.; Barry, T.L.; Petzinger, G. Isolation of a 2:1 hydrochlorothiazide-formaldehyde adduct impurity in hydrochlorothiazide drug substance by preparative chromatography and characterization by electrospray ionization LC-MS. J. Pharm. Biomed. Anal., 2001, 26, 651-663.
7. Rao, P.S.; Ray, U.K.; Gupta, P.B.; Rao, D.V.; Islam, A.; Rajput, P.; Mukkanti, K. Identification, isolation and characterization of new impurity in rabeprazole sodium. J. Pharm. Biomed. Anal., 2010, 52, 620-624.
8. Sakurai, M.; Abe, H.; Okamura, N.; Inoue, Y.; Akiyoshi, T.; Matsuyama, K.; Uchida, T.; Otsuka, M. Stability of gabexate mesilate products: Influence of the addition of mannitol. Biomed. Mater. Eng, 2010, 20, 13-20.
9. Zanitti, L.; Ferretti, R.; Gallinella, B.; La, T.F.; Sanna, M.L.; Mosca, A.; Cirilli, R. Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate. J. Pharm. Biomed. Anal., 2010, 52, 665-671.
10. Qiu, F.; Pennino, S.; Busacca, C.A.; Norwood, D.L. Identification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies. J. Pharm. Biomed. Anal., 2009, 49, 733-738.
11. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S.P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, S.R.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J.T.; Tweedie, D.; Vega, J.M.; Walsh, J.; Wrighton, S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol., 2003, 43, 443-469.
12. Yamazaki, H.; Guo, Z.; Persmark, M.; Mimura, M.; Inoue, K.; Guengerich, F.P.; Shimada, T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol., 1994, 46, 568-577.
13. Dayer, P.; Leemann, T.; Striberni, R. Dextromethorphan Odemethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin. Pharmacol. Ther., 1989, 45, 34-40.
14. Furuta, S.; Kamada, E.; Suzuki, T.; Sugimoto, T.; Kawabata, Y.; Shinozaki, Y.; Sano, H. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica, 2001, 31, 1-10.
15. Knodell, R.G.; Browne, D.G.; Gwozdz, G.P.; Brian, W.R.; Guengerich, F.P. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology, 1991, 101, 1680-1691.
16. Madeira, M.; Levine, M.; Chang, T.K.; Mirfazaelian, A.; Bellward, G.D. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos., 2004, 32, 460-467.
17. Shou, M.; Lin, Y.; Lu, P.; Tang, C.; Mei, Q.; Cui, D.; Tang, W.; Ngui, J.S.; Lin, C.C.; Singh, R.; Wong, B.K.; Yergey, J.A.; Lin, J.H.; Pearson, P.G.; Baillie, T.A.; Rodrigues, A.D.; Rushmore, T.H. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab, 2001, 2, 17-36.
18. Kuzmic, P.; Hill, C.; Kirtley, M.P.; Janc, J.W. Kinetic determination of tight-binding impurities in enzyme inhibitors. Anal. Biochem., 2003, 319, 272-279.
19. Delaporte, E.; Slaughter, D.E.; Egan, M.A.; Gatto, G.J.; Santos, A.; Shelley, J.; Price, E.; Howells, L.; Dean, D.C.; Rodrigues, A.D. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol. Screen., 2001, 6, 225-231.
20. Chauret, N.; Dobbs, B.; Lackman, R.L.; Bateman, K.; Nicoll-Griffith, D.A.; Stresser, D.M.; Ackermann, J.M.; Turner, S.D.; Miller, V.P.; Crespi, C.L. The use of 3-[2-(N, N-diethyl-Nmethylammonium) ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos., 2001, 29, 1196-1200.
21. Cohen, L.H.; Remley, M.J.; Raunig, D.; Vaz, A.D. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos., 2003, 31, 1005-1015.
22. Ma, B.; Prueksaritanont, T.; Lin, J.H. Drug interactions with calcium channel blockers: possible involvement of metaboliteintermediate complexation with CYP3A. Drug Metab Dispos., 2000, 28, 125-130.
23. Yin, H.; Racha, J.; Li, S.Y.; Olejnik, N.; Satoh, H.; Moore, D. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica, 2000, 30, 141-154.